Copyright Reports & Markets. All rights reserved.

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Squamous Non-Small Cell Lung Cancer Therapeutics

      • 1.1 Definition of Squamous Non-Small Cell Lung Cancer Therapeutics
      • 1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Type
        • 1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 BMS-906024
        • 1.2.3 Buparlisib Hydrochloride
        • 1.2.4 FP-1039
        • 1.2.5 Ipilimumab
        • 1.2.6 JNJ-42756493
        • 1.2.7 Lenvatinib
        • 1.2.8 Others
      • 1.3 Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Applications
        • 1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Research Center
        • 1.3.3 Hospital
        • 1.3.4 Clinic
      • 1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Overall Market
        • 1.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production (2014-2025)
        • 1.4.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.5 China Squamous Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.6 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.8 India Squamous Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Squamous Non-Small Cell Lung Cancer Therapeutics
      • 2.3 Manufacturing Process Analysis of Squamous Non-Small Cell Lung Cancer Therapeutics
      • 2.4 Industry Chain Structure of Squamous Non-Small Cell Lung Cancer Therapeutics

      3 Development and Manufacturing Plants Analysis of Squamous Non-Small Cell Lung Cancer Therapeutics

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Squamous Non-Small Cell Lung Cancer Therapeutics
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Squamous Non-Small Cell Lung Cancer Therapeutics Production and Capacity Analysis
      • 4.2 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Analysis
      • 4.3 Squamous Non-Small Cell Lung Cancer Therapeutics Price Analysis
      • 4.4 Market Concentration Degree

      5 Squamous Non-Small Cell Lung Cancer Therapeutics Regional Market Analysis

      • 5.1 Squamous Non-Small Cell Lung Cancer Therapeutics Production by Regions
        • 5.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production by Regions
        • 5.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Regions
      • 5.2 Squamous Non-Small Cell Lung Cancer Therapeutics Consumption by Regions
      • 5.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis
        • 5.3.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 5.3.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Import and Export
      • 5.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis
        • 5.4.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 5.4.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Import and Export
      • 5.5 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis
        • 5.5.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 5.5.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Squamous Non-Small Cell Lung Cancer Therapeutics Import and Export
      • 5.6 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis
        • 5.6.1 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 5.6.2 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Import and Export
      • 5.7 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis
        • 5.7.1 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 5.7.2 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Import and Export
      • 5.8 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis
        • 5.8.1 India Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 5.8.2 India Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Squamous Non-Small Cell Lung Cancer Therapeutics Import and Export

      6 Squamous Non-Small Cell Lung Cancer Therapeutics Segment Market Analysis (by Type)

      • 6.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production by Type
      • 6.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type
      • 6.3 Squamous Non-Small Cell Lung Cancer Therapeutics Price by Type

      7 Squamous Non-Small Cell Lung Cancer Therapeutics Segment Market Analysis (by Application)

      • 7.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption by Application
      • 7.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Market Share by Application (2014-2019)

      8 Squamous Non-Small Cell Lung Cancer Therapeutics Major Manufacturers Analysis

      • 8.1 Ascenta Therapeutics, Inc.
        • 8.1.1 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.1.2 Ascenta Therapeutics, Inc. Product Introduction, Application and Specification
        • 8.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 AstraZeneca Plc
        • 8.2.1 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.2.2 AstraZeneca Plc Product Introduction, Application and Specification
        • 8.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 AVEO Pharmaceuticals, Inc.
        • 8.3.1 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.3.2 AVEO Pharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Bayer AG
        • 8.4.1 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.4.2 Bayer AG Product Introduction, Application and Specification
        • 8.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 BIND Therapeutics, Inc.
        • 8.5.1 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.5.2 BIND Therapeutics, Inc. Product Introduction, Application and Specification
        • 8.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Boehringer Ingelheim GmbH
        • 8.6.1 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.6.2 Boehringer Ingelheim GmbH Product Introduction, Application and Specification
        • 8.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Bristol-Myers Squibb Company
        • 8.7.1 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.7.2 Bristol-Myers Squibb Company Product Introduction, Application and Specification
        • 8.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Eli Lilly and Company
        • 8.8.1 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.8.2 Eli Lilly and Company Product Introduction, Application and Specification
        • 8.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 F. Hoffmann-La Roche Ltd.
        • 8.9.1 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.9.2 F. Hoffmann-La Roche Ltd. Product Introduction, Application and Specification
        • 8.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Five Prime Therapeutics, Inc.
        • 8.10.1 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 8.10.2 Five Prime Therapeutics, Inc. Product Introduction, Application and Specification
        • 8.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Genentech, Inc.
      • 8.12 Incyte Corporation
      • 8.13 Johnson & Johnson
      • 8.14 MacroGenics, Inc.
      • 8.15 Novartis AG
      • 8.16 Oncogenex Pharmaceuticals, Inc.
      • 8.17 PsiOxus Therapeutics Limited

      9 Development Trend of Analysis of Squamous Non-Small Cell Lung Cancer Therapeutics Market

      • 9.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Trend Analysis
        • 9.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Squamous Non-Small Cell Lung Cancer Therapeutics Regional Market Trend
        • 9.2.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Forecast 2019-2025
        • 9.2.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Forecast 2019-2025
        • 9.2.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Forecast 2019-2025
        • 9.2.4 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Forecast 2019-2025
        • 9.2.5 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Forecast 2019-2025
        • 9.2.6 India Squamous Non-Small Cell Lung Cancer Therapeutics Forecast 2019-2025
      • 9.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Trend (Product Type)
      • 9.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Squamous Non-Small Cell Lung Cancer Therapeutics Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Squamous Non-Small Cell Lung Cancer Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Squamous Non-Small Cell Lung Cancer Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Squamous Non-Small Cell Lung Cancer Therapeutics market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Squamous Non-Small Cell Lung Cancer Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Squamous Non-Small Cell Lung Cancer Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Ascenta Therapeutics, Inc.
        AstraZeneca Plc
        AVEO Pharmaceuticals, Inc.
        Bayer AG
        BIND Therapeutics, Inc.
        Boehringer Ingelheim GmbH
        Bristol-Myers Squibb Company
        Eli Lilly and Company
        F. Hoffmann-La Roche Ltd.
        Five Prime Therapeutics, Inc.
        Genentech, Inc.
        Incyte Corporation
        Johnson & Johnson
        MacroGenics, Inc.
        Novartis AG
        Oncogenex Pharmaceuticals, Inc.
        PsiOxus Therapeutics Limited

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        BMS-906024
        Buparlisib Hydrochloride
        FP-1039
        Ipilimumab
        JNJ-42756493
        Lenvatinib
        Others

        Segment by Application
        Research Center
        Hospital
        Clinic

        Buy now